Wegovy and pancreatitis: what UK patients need to know and when to get urgent help
Pancreatitis is a serious condition involving inflammation of the pancreas, and it has been reported in some people taking Wegovy (semaglutide). In January 2026, the UK medicines regulator (MHRA) strengthened its safety warnings around this possible risk.
At the same time, the evidence so far suggests pancreatitis appears to be uncommon. Clinical trial data generally show very low rates, and some studies found rates similar to placebo groups. That means although risk should be taken seriously, it is not viewed as inevitable or common.
For most people, the most important thing is understanding the warning signs and being able to identify when symptoms need urgent medical attention.
What’s the link between Wegovy and pancreatitis?
Wegovy belongs to a group of medicines called GLP-1 receptor agonists. These medicines are used to support weight loss by helping people feel fuller for longer and reducing appetite.
The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that pancreatitis is a possible side effect of GLP-1 medicines including Wegovy. In rare cases, pancreatitis linked to these medicines has been reported as severe, including necrotising and fatal cases.
However, current evidence suggests the overall risk is low. Clinical trials involving semaglutide found pancreatitis occurred in a very small percentage of participants, generally around 0.1% to 0.3%. Some trial datasets found little difference between semaglutide and placebo groups.
For example, a Cleveland Clinic review summarising semaglutide trial data identified three pancreatitis cases among 1,306 participants, equivalent to around 0.23%.
That balance is important. Pancreatitis is serious and should never be ignored, but the evidence does not suggest that most Wegovy users will develop it.
This advice applies equally to both forms of Wegovy. The newly approved Wegovy tablets contain the same active ingredient as the injection (semaglutide), so the same pancreatitis precautions and warning signs apply whether you take the injection or the tablet.
How common is pancreatitis with Wegovy?
Based on the best available evidence, pancreatitis associated with Wegovy appears to be rare.
Clinical trials involving semaglutide consistently report low pancreatitis rates, and some studies found rates that were similar to people receiving placebo treatment instead of active medication. This matters because pancreatitis can happen even in people who are not taking weight loss medication at all.
At the same time, post-marketing safety reporting confirms that severe cases can occur. According to MHRA Yellow Card data, there were 1,296 UK reports of pancreatitis associated with GLP-1 receptor agonists between 2007 and October 2025, including 19 fatalities.
However, those reports cannot be used to calculate an exact personal risk. Yellow Card systems depend on voluntary reporting, and not every reported case is necessarily caused directly by the medicine itself. Experts reviewing the data have repeatedly cautioned against interpreting these figures as true incidence rates.
To put the reports into wider context, the MHRA estimates that around 1.6 million adults across England, Wales and Scotland used GLP-1 medication for weight loss between early 2024 and early 2025.
The most accurate way to frame the evidence is this: the absolute risk appears low, but the symptoms are important enough that patients should know what to watch for.
What symptoms should patients watch for?
The most important warning sign of pancreatitis is severe, persistent abdominal pain that does not improve.
The pain is often felt in the upper stomach area and may spread through to the back. Some people also experience nausea or vomiting alongside the pain.
It’s important not to self-diagnose pancreatitis based on mild digestive upset alone. Nausea, bloating and temporary stomach discomfort are common side effects when starting Wegovy and often improve over time.
The concern is the pattern and severity of symptoms rather than the presence of any stomach symptom at all.
Wegovy side effects or pancreatitis: how to tell the difference
This is one of the biggest worries for people taking Wegovy, because many of the medicine’s common side effects also affect the stomach and digestive system.
Typical Wegovy side effects can include:
- Mild nausea
- Bloating
- Loose stools or diarrhoea
- Mild stomach discomfort
- Reduced appetite
These symptoms are usually mild to moderate, often happen during dose increases, and commonly improve as the body adjusts to treatment.
Pancreatitis symptoms tend to look different. The pain is usually more severe, persistent and difficult to ignore. Rather than coming and going, it often continues or worsens over time. Repeated vomiting or pain spreading into the back can also be warning signs.
A helpful way to think about it is:
- Mild, temporary digestive symptoms are common with Wegovy
- Severe, persistent or unusual pain needs urgent medical review
Patients should focus on the severity, persistence and overall pattern of symptoms rather than assuming every stomach symptom means pancreatitis.
The MHRA specifically advises that severe persistent abdominal pain, with or without vomiting, should raise suspicion of pancreatitis.
When to get urgent help, and whether to stop Wegovy
If symptoms suggest possible pancreatitis, patients should seek urgent medical attention straight away.
Wegovy should be stopped immediately if pancreatitis is suspected while medical assessment takes place.
What to do if pancreatitis is suspected
- Stop taking Wegovy immediately
- Seek urgent medical advice through NHS 111, your GP, urgent care or A&E depending on severity
- Do not wait for your next routine appointment if pain is severe or worsening
- Follow medical advice regarding tests and further treatment
- Do not restart Wegovy if pancreatitis is confirmed unless specifically advised by a clinician
The MHRA’s January 2026 Drug Safety Update states:
Acting early is important because pancreatitis can become serious if left untreated.
Wegovy’s pancreatitis warning should be taken seriously, but the evidence does not support panic or blanket avoidance of treatment.
For most people, the key safety step is recognising the warning signs and knowing when symptoms need urgent review.
Key points to remember
- Pancreatitis linked to Wegovy appears to be uncommon
- Mild digestive side effects are common and usually improve over time
- Severe or persistent abdominal pain should never be ignored
- Patients with a history of previous pancreatitis or other risk factors should discuss this with their prescriber before treatment
- Early, urgent medical assessment matters if symptoms appear
Wegovy remains an effective weight loss treatment for many patients when prescribed appropriately and used with proper monitoring and support.
References
- MHRA Drug Safety Update, January 2026. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
- MHRA Yellow Card Safety Roundup, 2026. GLP-1 receptor agonist safety reporting data and prescribing context.
- Cleveland Clinic. Pancreatitis and GLP-1 medicines explainer reviewing semaglutide trial data.
- Medical News Today. Expert review of Ozempic and pancreatitis risk, including limitations of spontaneous safety reports.
- Ubie Health. Wegovy side effects guidance and patient symptom advice.
